Modified coagulation factors with prolonged in vivo half-life

US8754194B2 · kind B2 · utility

Assignee

• CSL Behring AG · DE

Inventors

• Stefan Schulte · Marburg, DE
• Thomas Weimer · Gladenbach, DE
• Hubert Metzner · Marburg, DE

Key dates

• Filing date: Dec 21, 2007
• Grant date: Jun 17, 2014
• Expiry date: Aug 17, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.